BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Vancouver - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Science in Vancouver
X-ORIGINAL-URL:https://scienceinvancouver.com
X-WR-CALDESC:Events for Science in Vancouver
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Vancouver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T100000
DTEND;TZID=America/Vancouver:20210923T130000
DTSTAMP:20260404T132655
CREATED:20210915T234450Z
LAST-MODIFIED:20210915T234450Z
UID:18337-1632304800-1632402000@scienceinvancouver.com
SUMMARY:UBC Tissue Clearing and Expansion 2021
DESCRIPTION:BCREGMED and the Dynamic Brain Circuits in Health & Disease team are excited to offer a TWO DAY online workshop to facilitate the use of tissue clearing and expansion techniques in the research lab. \nSeptember 22nd and 23rd\n10AM – 1PM both days\nZOOM \nPurpose\nBiological specimens are intrinsically difficult to image.  Currently used tools and methods\, which cut two-dimensional sections of tissue samples to provide insight into the cellular components\, lack in their ability to reveal the systemic nature of tissues and organs which are inherently three-dimensional. On the other hand\, imaging deep into intact tissues brings with it its own problems as a result of the obscuring effects of light scatter and the limitations of most commercial microscopes. \nTechniques to eliminate this scatter and provide understanding into the true behavior of tissues and organs have been developed\, however to our knowledge these techniques being under-utilized in research labs in BC due to their complexity and lack of appropriate equipment. With the recent purchase of a light sheet microscope for the School of Biomedical Engineering and a lattice light sheet microscope expected at the Centre for Brain Health\, tissue clearing and expansion will be made possible however training is needed on the various protocols of expansion and clearing\, 3D image analysis\, and troubleshooting to make sure these techniques are implemented effectively.
URL:https://scienceinvancouver.com/event/ubc-tissue-clearing-and-expansion-2021/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T100000
DTEND;TZID=America/Vancouver:20210923T130000
DTSTAMP:20260404T132655
CREATED:20210915T234450Z
LAST-MODIFIED:20210915T234450Z
UID:26435-1632304800-1632402000@scienceinvancouver.com
SUMMARY:UBC Tissue Clearing and Expansion 2021
DESCRIPTION:BCREGMED and the Dynamic Brain Circuits in Health & Disease team are excited to offer a TWO DAY online workshop to facilitate the use of tissue clearing and expansion techniques in the research lab. \nSeptember 22nd and 23rd\n10AM – 1PM both days\nZOOM \nPurpose\nBiological specimens are intrinsically difficult to image.  Currently used tools and methods\, which cut two-dimensional sections of tissue samples to provide insight into the cellular components\, lack in their ability to reveal the systemic nature of tissues and organs which are inherently three-dimensional. On the other hand\, imaging deep into intact tissues brings with it its own problems as a result of the obscuring effects of light scatter and the limitations of most commercial microscopes. \nTechniques to eliminate this scatter and provide understanding into the true behavior of tissues and organs have been developed\, however to our knowledge these techniques being under-utilized in research labs in BC due to their complexity and lack of appropriate equipment. With the recent purchase of a light sheet microscope for the School of Biomedical Engineering and a lattice light sheet microscope expected at the Centre for Brain Health\, tissue clearing and expansion will be made possible however training is needed on the various protocols of expansion and clearing\, 3D image analysis\, and troubleshooting to make sure these techniques are implemented effectively.
URL:https://scienceinvancouver.com/event/ubc-tissue-clearing-and-expansion-2021-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T100000
DTEND;TZID=America/Vancouver:20210923T130000
DTSTAMP:20260404T132655
CREATED:20210915T234450Z
LAST-MODIFIED:20210915T234450Z
UID:28050-1632304800-1632402000@scienceinvancouver.com
SUMMARY:UBC Tissue Clearing and Expansion 2021
DESCRIPTION:BCREGMED and the Dynamic Brain Circuits in Health & Disease team are excited to offer a TWO DAY online workshop to facilitate the use of tissue clearing and expansion techniques in the research lab. \nSeptember 22nd and 23rd\n10AM – 1PM both days\nZOOM \nPurpose\nBiological specimens are intrinsically difficult to image.  Currently used tools and methods\, which cut two-dimensional sections of tissue samples to provide insight into the cellular components\, lack in their ability to reveal the systemic nature of tissues and organs which are inherently three-dimensional. On the other hand\, imaging deep into intact tissues brings with it its own problems as a result of the obscuring effects of light scatter and the limitations of most commercial microscopes. \nTechniques to eliminate this scatter and provide understanding into the true behavior of tissues and organs have been developed\, however to our knowledge these techniques being under-utilized in research labs in BC due to their complexity and lack of appropriate equipment. With the recent purchase of a light sheet microscope for the School of Biomedical Engineering and a lattice light sheet microscope expected at the Centre for Brain Health\, tissue clearing and expansion will be made possible however training is needed on the various protocols of expansion and clearing\, 3D image analysis\, and troubleshooting to make sure these techniques are implemented effectively.
URL:https://scienceinvancouver.com/event/ubc-tissue-clearing-and-expansion-2021-3/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T100000
DTEND;TZID=America/Vancouver:20210923T130000
DTSTAMP:20260404T132655
CREATED:20210915T234450Z
LAST-MODIFIED:20210915T234450Z
UID:31133-1632304800-1632402000@scienceinvancouver.com
SUMMARY:UBC Tissue Clearing and Expansion 2021
DESCRIPTION:BCREGMED and the Dynamic Brain Circuits in Health & Disease team are excited to offer a TWO DAY online workshop to facilitate the use of tissue clearing and expansion techniques in the research lab. \nSeptember 22nd and 23rd\n10AM – 1PM both days\nZOOM \nPurpose\nBiological specimens are intrinsically difficult to image.  Currently used tools and methods\, which cut two-dimensional sections of tissue samples to provide insight into the cellular components\, lack in their ability to reveal the systemic nature of tissues and organs which are inherently three-dimensional. On the other hand\, imaging deep into intact tissues brings with it its own problems as a result of the obscuring effects of light scatter and the limitations of most commercial microscopes. \nTechniques to eliminate this scatter and provide understanding into the true behavior of tissues and organs have been developed\, however to our knowledge these techniques being under-utilized in research labs in BC due to their complexity and lack of appropriate equipment. With the recent purchase of a light sheet microscope for the School of Biomedical Engineering and a lattice light sheet microscope expected at the Centre for Brain Health\, tissue clearing and expansion will be made possible however training is needed on the various protocols of expansion and clearing\, 3D image analysis\, and troubleshooting to make sure these techniques are implemented effectively.
URL:https://scienceinvancouver.com/event/ubc-tissue-clearing-and-expansion-2021-4/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T100000
DTEND;TZID=America/Vancouver:20210923T130000
DTSTAMP:20260404T132655
CREATED:20210915T234450Z
LAST-MODIFIED:20210915T234450Z
UID:32593-1632304800-1632402000@scienceinvancouver.com
SUMMARY:UBC Tissue Clearing and Expansion 2021
DESCRIPTION:BCREGMED and the Dynamic Brain Circuits in Health & Disease team are excited to offer a TWO DAY online workshop to facilitate the use of tissue clearing and expansion techniques in the research lab. \nSeptember 22nd and 23rd\n10AM – 1PM both days\nZOOM \nPurpose\nBiological specimens are intrinsically difficult to image.  Currently used tools and methods\, which cut two-dimensional sections of tissue samples to provide insight into the cellular components\, lack in their ability to reveal the systemic nature of tissues and organs which are inherently three-dimensional. On the other hand\, imaging deep into intact tissues brings with it its own problems as a result of the obscuring effects of light scatter and the limitations of most commercial microscopes. \nTechniques to eliminate this scatter and provide understanding into the true behavior of tissues and organs have been developed\, however to our knowledge these techniques being under-utilized in research labs in BC due to their complexity and lack of appropriate equipment. With the recent purchase of a light sheet microscope for the School of Biomedical Engineering and a lattice light sheet microscope expected at the Centre for Brain Health\, tissue clearing and expansion will be made possible however training is needed on the various protocols of expansion and clearing\, 3D image analysis\, and troubleshooting to make sure these techniques are implemented effectively.
URL:https://scienceinvancouver.com/event/ubc-tissue-clearing-and-expansion-2021-5/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T120000
DTEND;TZID=America/Vancouver:20210922T130000
DTSTAMP:20260404T132655
CREATED:20210920T185145Z
LAST-MODIFIED:20210920T185145Z
UID:18399-1632312000-1632315600@scienceinvancouver.com
SUMMARY:Emergent Global Pandemic Threats: Origin\, Spread\, and Adaptation of SARS-CoV-2
DESCRIPTION:Learning Series Event \nAudience: General Public \nWednesday\, September 22\, 2021\, 12:00 pm – 1:00 pm\nLocation: Register online at: https://attendee.gotowebinar.com/register/6491115742922274573 \n  \nThis webinar will be presented by: \nJeffrey Joy\nSenior Scientist\, Molecular Epidemiology and Evolutionary Genetics Group\nBC Centre for Excellence in HIV/AIDS\nAssistant Professor of Medicine\nUniversity of British Columbia \nWebinar Main Objectives:\nUpon completion of this session participants will be able to discuss: \n\nCurrent and emerging pandemic threats\nThe global origins and dissemination of SARS-CoV-2\nThe introductions of SARS-CoV-2 into Canada\nThe dynamics of SARS-CoV-2 variants\nThe molecular evolution of SARS-Cov-2\n\nThe presentation will be followed by a question and answer period where participants will have the opportunity to ask questions and receive real time responses from the presenter. \n\nCost: Free registration. \nPlease register for the webinar by clicking the following link: \nCLICK HERE. \nIf you are unable to attend the live webinar it will be recorded and available for viewing on BC-CfE’s Education and Training website at: education.bccfe.ca/webinars \nThis event is accredited by the College of Family Physicians of Canada and the British Columbia Chapter for up to 1 Mainpro+ credits. \nIf you have any questions regarding this event\, please contact BC-CfE’s Education and Training team at: education@bccfe.ca. \n 
URL:https://scienceinvancouver.com/event/emergent-global-pandemic-threats-origin-spread-and-adaptation-of-sars-cov-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T120000
DTEND;TZID=America/Vancouver:20210922T130000
DTSTAMP:20260404T132655
CREATED:20210920T185145Z
LAST-MODIFIED:20210920T185145Z
UID:26439-1632312000-1632315600@scienceinvancouver.com
SUMMARY:Emergent Global Pandemic Threats: Origin\, Spread\, and Adaptation of SARS-CoV-2
DESCRIPTION:Learning Series Event \nAudience: General Public \nWednesday\, September 22\, 2021\, 12:00 pm – 1:00 pm\nLocation: Register online at: https://attendee.gotowebinar.com/register/6491115742922274573 \n  \nThis webinar will be presented by: \nJeffrey Joy\nSenior Scientist\, Molecular Epidemiology and Evolutionary Genetics Group\nBC Centre for Excellence in HIV/AIDS\nAssistant Professor of Medicine\nUniversity of British Columbia \nWebinar Main Objectives:\nUpon completion of this session participants will be able to discuss: \n\nCurrent and emerging pandemic threats\nThe global origins and dissemination of SARS-CoV-2\nThe introductions of SARS-CoV-2 into Canada\nThe dynamics of SARS-CoV-2 variants\nThe molecular evolution of SARS-Cov-2\n\nThe presentation will be followed by a question and answer period where participants will have the opportunity to ask questions and receive real time responses from the presenter. \n\nCost: Free registration. \nPlease register for the webinar by clicking the following link: \nCLICK HERE. \nIf you are unable to attend the live webinar it will be recorded and available for viewing on BC-CfE’s Education and Training website at: education.bccfe.ca/webinars \nThis event is accredited by the College of Family Physicians of Canada and the British Columbia Chapter for up to 1 Mainpro+ credits. \nIf you have any questions regarding this event\, please contact BC-CfE’s Education and Training team at: education@bccfe.ca. \n 
URL:https://scienceinvancouver.com/event/emergent-global-pandemic-threats-origin-spread-and-adaptation-of-sars-cov-2-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T120000
DTEND;TZID=America/Vancouver:20210922T130000
DTSTAMP:20260404T132655
CREATED:20210920T185145Z
LAST-MODIFIED:20210920T185145Z
UID:28054-1632312000-1632315600@scienceinvancouver.com
SUMMARY:Emergent Global Pandemic Threats: Origin\, Spread\, and Adaptation of SARS-CoV-2
DESCRIPTION:Learning Series Event \nAudience: General Public \nWednesday\, September 22\, 2021\, 12:00 pm – 1:00 pm\nLocation: Register online at: https://attendee.gotowebinar.com/register/6491115742922274573 \n  \nThis webinar will be presented by: \nJeffrey Joy\nSenior Scientist\, Molecular Epidemiology and Evolutionary Genetics Group\nBC Centre for Excellence in HIV/AIDS\nAssistant Professor of Medicine\nUniversity of British Columbia \nWebinar Main Objectives:\nUpon completion of this session participants will be able to discuss: \n\nCurrent and emerging pandemic threats\nThe global origins and dissemination of SARS-CoV-2\nThe introductions of SARS-CoV-2 into Canada\nThe dynamics of SARS-CoV-2 variants\nThe molecular evolution of SARS-Cov-2\n\nThe presentation will be followed by a question and answer period where participants will have the opportunity to ask questions and receive real time responses from the presenter. \n\nCost: Free registration. \nPlease register for the webinar by clicking the following link: \nCLICK HERE. \nIf you are unable to attend the live webinar it will be recorded and available for viewing on BC-CfE’s Education and Training website at: education.bccfe.ca/webinars \nThis event is accredited by the College of Family Physicians of Canada and the British Columbia Chapter for up to 1 Mainpro+ credits. \nIf you have any questions regarding this event\, please contact BC-CfE’s Education and Training team at: education@bccfe.ca. \n 
URL:https://scienceinvancouver.com/event/emergent-global-pandemic-threats-origin-spread-and-adaptation-of-sars-cov-2-3/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T120000
DTEND;TZID=America/Vancouver:20210922T130000
DTSTAMP:20260404T132655
CREATED:20210920T185145Z
LAST-MODIFIED:20210920T185145Z
UID:31137-1632312000-1632315600@scienceinvancouver.com
SUMMARY:Emergent Global Pandemic Threats: Origin\, Spread\, and Adaptation of SARS-CoV-2
DESCRIPTION:Learning Series Event \nAudience: General Public \nWednesday\, September 22\, 2021\, 12:00 pm – 1:00 pm\nLocation: Register online at: https://attendee.gotowebinar.com/register/6491115742922274573 \n  \nThis webinar will be presented by: \nJeffrey Joy\nSenior Scientist\, Molecular Epidemiology and Evolutionary Genetics Group\nBC Centre for Excellence in HIV/AIDS\nAssistant Professor of Medicine\nUniversity of British Columbia \nWebinar Main Objectives:\nUpon completion of this session participants will be able to discuss: \n\nCurrent and emerging pandemic threats\nThe global origins and dissemination of SARS-CoV-2\nThe introductions of SARS-CoV-2 into Canada\nThe dynamics of SARS-CoV-2 variants\nThe molecular evolution of SARS-Cov-2\n\nThe presentation will be followed by a question and answer period where participants will have the opportunity to ask questions and receive real time responses from the presenter. \n\nCost: Free registration. \nPlease register for the webinar by clicking the following link: \nCLICK HERE. \nIf you are unable to attend the live webinar it will be recorded and available for viewing on BC-CfE’s Education and Training website at: education.bccfe.ca/webinars \nThis event is accredited by the College of Family Physicians of Canada and the British Columbia Chapter for up to 1 Mainpro+ credits. \nIf you have any questions regarding this event\, please contact BC-CfE’s Education and Training team at: education@bccfe.ca. \n 
URL:https://scienceinvancouver.com/event/emergent-global-pandemic-threats-origin-spread-and-adaptation-of-sars-cov-2-4/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T120000
DTEND;TZID=America/Vancouver:20210922T130000
DTSTAMP:20260404T132655
CREATED:20210920T185145Z
LAST-MODIFIED:20210920T185145Z
UID:32597-1632312000-1632315600@scienceinvancouver.com
SUMMARY:Emergent Global Pandemic Threats: Origin\, Spread\, and Adaptation of SARS-CoV-2
DESCRIPTION:Learning Series Event \nAudience: General Public \nWednesday\, September 22\, 2021\, 12:00 pm – 1:00 pm\nLocation: Register online at: https://attendee.gotowebinar.com/register/6491115742922274573 \n  \nThis webinar will be presented by: \nJeffrey Joy\nSenior Scientist\, Molecular Epidemiology and Evolutionary Genetics Group\nBC Centre for Excellence in HIV/AIDS\nAssistant Professor of Medicine\nUniversity of British Columbia \nWebinar Main Objectives:\nUpon completion of this session participants will be able to discuss: \n\nCurrent and emerging pandemic threats\nThe global origins and dissemination of SARS-CoV-2\nThe introductions of SARS-CoV-2 into Canada\nThe dynamics of SARS-CoV-2 variants\nThe molecular evolution of SARS-Cov-2\n\nThe presentation will be followed by a question and answer period where participants will have the opportunity to ask questions and receive real time responses from the presenter. \n\nCost: Free registration. \nPlease register for the webinar by clicking the following link: \nCLICK HERE. \nIf you are unable to attend the live webinar it will be recorded and available for viewing on BC-CfE’s Education and Training website at: education.bccfe.ca/webinars \nThis event is accredited by the College of Family Physicians of Canada and the British Columbia Chapter for up to 1 Mainpro+ credits. \nIf you have any questions regarding this event\, please contact BC-CfE’s Education and Training team at: education@bccfe.ca. \n 
URL:https://scienceinvancouver.com/event/emergent-global-pandemic-threats-origin-spread-and-adaptation-of-sars-cov-2-5/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T120000
DTEND;TZID=America/Vancouver:20210922T150000
DTSTAMP:20260404T132655
CREATED:20210825T193724Z
LAST-MODIFIED:20210825T193724Z
UID:18001-1632312000-1632322800@scienceinvancouver.com
SUMMARY:Speaker Series: Physical Activity & Mental Wellness
DESCRIPTION:Program \n\n\n\n\nIs Sweat the Best Antidepressant?\n12:00–1:00 PM PDT (UTC -7 hours)\nGuy Faulkner\, PhD\nUniversity of British Columbia\, Canada \nTo Live is to Fight: Depression\, Muay Thai\, and A Journey Towards Wellness in the Midst of a Global Pandemic\n1:00–2:00 PM PDT (UTC -7 hours)\nAlberto Almeida\, MPH\nProvidence Health Care\, Canada \nSocially Connected Physical Activity: What\, Why\, and How?\n2:00–3:00 PM PDT (UTC -7 hours)\nMark Beauchamp\, PhD\nUniversity of British Columbia\, Canada
URL:https://scienceinvancouver.com/event/speaker-series-physical-activity-mental-wellness/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T120000
DTEND;TZID=America/Vancouver:20210922T150000
DTSTAMP:20260404T132655
CREATED:20210825T193724Z
LAST-MODIFIED:20210825T193724Z
UID:26425-1632312000-1632322800@scienceinvancouver.com
SUMMARY:Speaker Series: Physical Activity & Mental Wellness
DESCRIPTION:Program \n\n\n\n\nIs Sweat the Best Antidepressant?\n12:00–1:00 PM PDT (UTC -7 hours)\nGuy Faulkner\, PhD\nUniversity of British Columbia\, Canada \nTo Live is to Fight: Depression\, Muay Thai\, and A Journey Towards Wellness in the Midst of a Global Pandemic\n1:00–2:00 PM PDT (UTC -7 hours)\nAlberto Almeida\, MPH\nProvidence Health Care\, Canada \nSocially Connected Physical Activity: What\, Why\, and How?\n2:00–3:00 PM PDT (UTC -7 hours)\nMark Beauchamp\, PhD\nUniversity of British Columbia\, Canada
URL:https://scienceinvancouver.com/event/speaker-series-physical-activity-mental-wellness-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T120000
DTEND;TZID=America/Vancouver:20210922T150000
DTSTAMP:20260404T132655
CREATED:20210825T193724Z
LAST-MODIFIED:20210825T193724Z
UID:28040-1632312000-1632322800@scienceinvancouver.com
SUMMARY:Speaker Series: Physical Activity & Mental Wellness
DESCRIPTION:Program \n\n\n\n\nIs Sweat the Best Antidepressant?\n12:00–1:00 PM PDT (UTC -7 hours)\nGuy Faulkner\, PhD\nUniversity of British Columbia\, Canada \nTo Live is to Fight: Depression\, Muay Thai\, and A Journey Towards Wellness in the Midst of a Global Pandemic\n1:00–2:00 PM PDT (UTC -7 hours)\nAlberto Almeida\, MPH\nProvidence Health Care\, Canada \nSocially Connected Physical Activity: What\, Why\, and How?\n2:00–3:00 PM PDT (UTC -7 hours)\nMark Beauchamp\, PhD\nUniversity of British Columbia\, Canada
URL:https://scienceinvancouver.com/event/speaker-series-physical-activity-mental-wellness-3/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T120000
DTEND;TZID=America/Vancouver:20210922T150000
DTSTAMP:20260404T132655
CREATED:20210825T193724Z
LAST-MODIFIED:20210825T193724Z
UID:31123-1632312000-1632322800@scienceinvancouver.com
SUMMARY:Speaker Series: Physical Activity & Mental Wellness
DESCRIPTION:Program \n\n\n\n\nIs Sweat the Best Antidepressant?\n12:00–1:00 PM PDT (UTC -7 hours)\nGuy Faulkner\, PhD\nUniversity of British Columbia\, Canada \nTo Live is to Fight: Depression\, Muay Thai\, and A Journey Towards Wellness in the Midst of a Global Pandemic\n1:00–2:00 PM PDT (UTC -7 hours)\nAlberto Almeida\, MPH\nProvidence Health Care\, Canada \nSocially Connected Physical Activity: What\, Why\, and How?\n2:00–3:00 PM PDT (UTC -7 hours)\nMark Beauchamp\, PhD\nUniversity of British Columbia\, Canada
URL:https://scienceinvancouver.com/event/speaker-series-physical-activity-mental-wellness-4/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T120000
DTEND;TZID=America/Vancouver:20210922T150000
DTSTAMP:20260404T132655
CREATED:20210825T193724Z
LAST-MODIFIED:20210825T193724Z
UID:32583-1632312000-1632322800@scienceinvancouver.com
SUMMARY:Speaker Series: Physical Activity & Mental Wellness
DESCRIPTION:Program \n\n\n\n\nIs Sweat the Best Antidepressant?\n12:00–1:00 PM PDT (UTC -7 hours)\nGuy Faulkner\, PhD\nUniversity of British Columbia\, Canada \nTo Live is to Fight: Depression\, Muay Thai\, and A Journey Towards Wellness in the Midst of a Global Pandemic\n1:00–2:00 PM PDT (UTC -7 hours)\nAlberto Almeida\, MPH\nProvidence Health Care\, Canada \nSocially Connected Physical Activity: What\, Why\, and How?\n2:00–3:00 PM PDT (UTC -7 hours)\nMark Beauchamp\, PhD\nUniversity of British Columbia\, Canada
URL:https://scienceinvancouver.com/event/speaker-series-physical-activity-mental-wellness-5/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210923T120000
DTEND;TZID=America/Vancouver:20210923T131500
DTSTAMP:20260404T132655
CREATED:20210908T231405Z
LAST-MODIFIED:20210908T231405Z
UID:18214-1632398400-1632402900@scienceinvancouver.com
SUMMARY:Emulating Target Trials to Strengthen the Evidence Base for the Clinical Management of Opioid Use Disorder
DESCRIPTION:Abstract \nIn 2016\, following a dramatic increase in opioid-related overdose deaths\, the province of British Columbia (BC)\, Canada declared a public health emergency. Opioid agonist treatment (OAT) is among the most effective tools available to combat the epidemic. However\, OAT uptake and retention is sub-optimal in BC and internationally\, compromised largely by social and structural factors but also deviations from evidence-based standards of care and fragmented care\, particularly for those with concurrent disorders. Furthermore\, a number of aspects of Canadian and US clinical guidelines for the management of opioid use disorder are based on limited and low-quality evidence. This proposal aims to apply cutting-edge methods for causal inference in emulating a series of ‘target trials’ using BC’s extensive population-based linked administrative databases. The target trial framework channels counterfactual theory in providing a flexible basis for comparing the effects of treatment and clinical management strategies on either an intent-to-treat or per-protocol basis. \nBio \nBohdan Nosyk is an Associate Professor and St. Paul’s Hospital CANFAR Chair in HIV/AIDS Research at the Faculty of Health Sciences\, and leads the Health Economic Research Unit at the BC Centre for Excellence in HIV/AIDS. Dr. Nosyk’s research seeks to inform complex policy decisions surrounding the prevention and management of HIV/AIDS and substance use disorders. He has led population-level evaluations in these disease areas in China\, in the state of California and across urban centers in the US\, and locally in British Columbia. He combines simulation modeling methods and cost-effectiveness analyses with econometric and biostatistical analyses of health administrative data to address these issues. \n\nThis seminar will be held virtually over Zoom and recorded: https://sfu.zoom.us/j/69219598229?pwd=ZnZCVnR4NmNBbnpyc1FQbDVQWFFVUT09 \nMeeting ID: 692 1959 8229 Password: 314185\nPlease visit the FHS Seminar Series webpage for further details: http://www.sfu.ca/fhs/news-events/events/seminar-series.html\nThe SFU FHS Research Seminar Series is open to the SFU and the broader research community.\nThe SFU FHS Research Seminar Series is an Accredited Small Group Learning by the Royal College of Physicians and Surgeons.
URL:https://scienceinvancouver.com/event/emulating-target-trials-to-strengthen-the-evidence-base-for-the-clinical-management-of-opioid-use-disorder/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210923T120000
DTEND;TZID=America/Vancouver:20210923T131500
DTSTAMP:20260404T132655
CREATED:20210908T231405Z
LAST-MODIFIED:20210908T231405Z
UID:26432-1632398400-1632402900@scienceinvancouver.com
SUMMARY:Emulating Target Trials to Strengthen the Evidence Base for the Clinical Management of Opioid Use Disorder
DESCRIPTION:Abstract \nIn 2016\, following a dramatic increase in opioid-related overdose deaths\, the province of British Columbia (BC)\, Canada declared a public health emergency. Opioid agonist treatment (OAT) is among the most effective tools available to combat the epidemic. However\, OAT uptake and retention is sub-optimal in BC and internationally\, compromised largely by social and structural factors but also deviations from evidence-based standards of care and fragmented care\, particularly for those with concurrent disorders. Furthermore\, a number of aspects of Canadian and US clinical guidelines for the management of opioid use disorder are based on limited and low-quality evidence. This proposal aims to apply cutting-edge methods for causal inference in emulating a series of ‘target trials’ using BC’s extensive population-based linked administrative databases. The target trial framework channels counterfactual theory in providing a flexible basis for comparing the effects of treatment and clinical management strategies on either an intent-to-treat or per-protocol basis. \nBio \nBohdan Nosyk is an Associate Professor and St. Paul’s Hospital CANFAR Chair in HIV/AIDS Research at the Faculty of Health Sciences\, and leads the Health Economic Research Unit at the BC Centre for Excellence in HIV/AIDS. Dr. Nosyk’s research seeks to inform complex policy decisions surrounding the prevention and management of HIV/AIDS and substance use disorders. He has led population-level evaluations in these disease areas in China\, in the state of California and across urban centers in the US\, and locally in British Columbia. He combines simulation modeling methods and cost-effectiveness analyses with econometric and biostatistical analyses of health administrative data to address these issues. \n\nThis seminar will be held virtually over Zoom and recorded: https://sfu.zoom.us/j/69219598229?pwd=ZnZCVnR4NmNBbnpyc1FQbDVQWFFVUT09 \nMeeting ID: 692 1959 8229 Password: 314185\nPlease visit the FHS Seminar Series webpage for further details: http://www.sfu.ca/fhs/news-events/events/seminar-series.html\nThe SFU FHS Research Seminar Series is open to the SFU and the broader research community.\nThe SFU FHS Research Seminar Series is an Accredited Small Group Learning by the Royal College of Physicians and Surgeons.
URL:https://scienceinvancouver.com/event/emulating-target-trials-to-strengthen-the-evidence-base-for-the-clinical-management-of-opioid-use-disorder-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210923T120000
DTEND;TZID=America/Vancouver:20210923T131500
DTSTAMP:20260404T132655
CREATED:20210908T231405Z
LAST-MODIFIED:20210908T231405Z
UID:28047-1632398400-1632402900@scienceinvancouver.com
SUMMARY:Emulating Target Trials to Strengthen the Evidence Base for the Clinical Management of Opioid Use Disorder
DESCRIPTION:Abstract \nIn 2016\, following a dramatic increase in opioid-related overdose deaths\, the province of British Columbia (BC)\, Canada declared a public health emergency. Opioid agonist treatment (OAT) is among the most effective tools available to combat the epidemic. However\, OAT uptake and retention is sub-optimal in BC and internationally\, compromised largely by social and structural factors but also deviations from evidence-based standards of care and fragmented care\, particularly for those with concurrent disorders. Furthermore\, a number of aspects of Canadian and US clinical guidelines for the management of opioid use disorder are based on limited and low-quality evidence. This proposal aims to apply cutting-edge methods for causal inference in emulating a series of ‘target trials’ using BC’s extensive population-based linked administrative databases. The target trial framework channels counterfactual theory in providing a flexible basis for comparing the effects of treatment and clinical management strategies on either an intent-to-treat or per-protocol basis. \nBio \nBohdan Nosyk is an Associate Professor and St. Paul’s Hospital CANFAR Chair in HIV/AIDS Research at the Faculty of Health Sciences\, and leads the Health Economic Research Unit at the BC Centre for Excellence in HIV/AIDS. Dr. Nosyk’s research seeks to inform complex policy decisions surrounding the prevention and management of HIV/AIDS and substance use disorders. He has led population-level evaluations in these disease areas in China\, in the state of California and across urban centers in the US\, and locally in British Columbia. He combines simulation modeling methods and cost-effectiveness analyses with econometric and biostatistical analyses of health administrative data to address these issues. \n\nThis seminar will be held virtually over Zoom and recorded: https://sfu.zoom.us/j/69219598229?pwd=ZnZCVnR4NmNBbnpyc1FQbDVQWFFVUT09 \nMeeting ID: 692 1959 8229 Password: 314185\nPlease visit the FHS Seminar Series webpage for further details: http://www.sfu.ca/fhs/news-events/events/seminar-series.html\nThe SFU FHS Research Seminar Series is open to the SFU and the broader research community.\nThe SFU FHS Research Seminar Series is an Accredited Small Group Learning by the Royal College of Physicians and Surgeons.
URL:https://scienceinvancouver.com/event/emulating-target-trials-to-strengthen-the-evidence-base-for-the-clinical-management-of-opioid-use-disorder-3/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210923T120000
DTEND;TZID=America/Vancouver:20210923T131500
DTSTAMP:20260404T132655
CREATED:20210908T231405Z
LAST-MODIFIED:20210908T231405Z
UID:31131-1632398400-1632402900@scienceinvancouver.com
SUMMARY:Emulating Target Trials to Strengthen the Evidence Base for the Clinical Management of Opioid Use Disorder
DESCRIPTION:Abstract \nIn 2016\, following a dramatic increase in opioid-related overdose deaths\, the province of British Columbia (BC)\, Canada declared a public health emergency. Opioid agonist treatment (OAT) is among the most effective tools available to combat the epidemic. However\, OAT uptake and retention is sub-optimal in BC and internationally\, compromised largely by social and structural factors but also deviations from evidence-based standards of care and fragmented care\, particularly for those with concurrent disorders. Furthermore\, a number of aspects of Canadian and US clinical guidelines for the management of opioid use disorder are based on limited and low-quality evidence. This proposal aims to apply cutting-edge methods for causal inference in emulating a series of ‘target trials’ using BC’s extensive population-based linked administrative databases. The target trial framework channels counterfactual theory in providing a flexible basis for comparing the effects of treatment and clinical management strategies on either an intent-to-treat or per-protocol basis. \nBio \nBohdan Nosyk is an Associate Professor and St. Paul’s Hospital CANFAR Chair in HIV/AIDS Research at the Faculty of Health Sciences\, and leads the Health Economic Research Unit at the BC Centre for Excellence in HIV/AIDS. Dr. Nosyk’s research seeks to inform complex policy decisions surrounding the prevention and management of HIV/AIDS and substance use disorders. He has led population-level evaluations in these disease areas in China\, in the state of California and across urban centers in the US\, and locally in British Columbia. He combines simulation modeling methods and cost-effectiveness analyses with econometric and biostatistical analyses of health administrative data to address these issues. \n\nThis seminar will be held virtually over Zoom and recorded: https://sfu.zoom.us/j/69219598229?pwd=ZnZCVnR4NmNBbnpyc1FQbDVQWFFVUT09 \nMeeting ID: 692 1959 8229 Password: 314185\nPlease visit the FHS Seminar Series webpage for further details: http://www.sfu.ca/fhs/news-events/events/seminar-series.html\nThe SFU FHS Research Seminar Series is open to the SFU and the broader research community.\nThe SFU FHS Research Seminar Series is an Accredited Small Group Learning by the Royal College of Physicians and Surgeons.
URL:https://scienceinvancouver.com/event/emulating-target-trials-to-strengthen-the-evidence-base-for-the-clinical-management-of-opioid-use-disorder-4/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210923T120000
DTEND;TZID=America/Vancouver:20210923T131500
DTSTAMP:20260404T132655
CREATED:20210908T231405Z
LAST-MODIFIED:20210908T231405Z
UID:32591-1632398400-1632402900@scienceinvancouver.com
SUMMARY:Emulating Target Trials to Strengthen the Evidence Base for the Clinical Management of Opioid Use Disorder
DESCRIPTION:Abstract \nIn 2016\, following a dramatic increase in opioid-related overdose deaths\, the province of British Columbia (BC)\, Canada declared a public health emergency. Opioid agonist treatment (OAT) is among the most effective tools available to combat the epidemic. However\, OAT uptake and retention is sub-optimal in BC and internationally\, compromised largely by social and structural factors but also deviations from evidence-based standards of care and fragmented care\, particularly for those with concurrent disorders. Furthermore\, a number of aspects of Canadian and US clinical guidelines for the management of opioid use disorder are based on limited and low-quality evidence. This proposal aims to apply cutting-edge methods for causal inference in emulating a series of ‘target trials’ using BC’s extensive population-based linked administrative databases. The target trial framework channels counterfactual theory in providing a flexible basis for comparing the effects of treatment and clinical management strategies on either an intent-to-treat or per-protocol basis. \nBio \nBohdan Nosyk is an Associate Professor and St. Paul’s Hospital CANFAR Chair in HIV/AIDS Research at the Faculty of Health Sciences\, and leads the Health Economic Research Unit at the BC Centre for Excellence in HIV/AIDS. Dr. Nosyk’s research seeks to inform complex policy decisions surrounding the prevention and management of HIV/AIDS and substance use disorders. He has led population-level evaluations in these disease areas in China\, in the state of California and across urban centers in the US\, and locally in British Columbia. He combines simulation modeling methods and cost-effectiveness analyses with econometric and biostatistical analyses of health administrative data to address these issues. \n\nThis seminar will be held virtually over Zoom and recorded: https://sfu.zoom.us/j/69219598229?pwd=ZnZCVnR4NmNBbnpyc1FQbDVQWFFVUT09 \nMeeting ID: 692 1959 8229 Password: 314185\nPlease visit the FHS Seminar Series webpage for further details: http://www.sfu.ca/fhs/news-events/events/seminar-series.html\nThe SFU FHS Research Seminar Series is open to the SFU and the broader research community.\nThe SFU FHS Research Seminar Series is an Accredited Small Group Learning by the Royal College of Physicians and Surgeons.
URL:https://scienceinvancouver.com/event/emulating-target-trials-to-strengthen-the-evidence-base-for-the-clinical-management-of-opioid-use-disorder-5/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210923T140000
DTEND;TZID=America/Vancouver:20210923T160000
DTSTAMP:20260404T132655
CREATED:20210813T195336Z
LAST-MODIFIED:20210813T195336Z
UID:17846-1632405600-1632412800@scienceinvancouver.com
SUMMARY:23rd Annual Life Sciences BC Awards
DESCRIPTION:The 23rd Annual Life Sciences BC Awards presented by FARRIS is an opportunity to celebrate the life science sector’s many achievements amongst peers\, family and friends. As Canada’s fastest-growing life sciences sector\, our British Columbia ecosystem has never been stronger seeing unprecedented momentum in scientific discovery\, innovation\, and attraction of capital and talent. In addition\, BC life science innovation has been at the forefront of the global response to COVID-19. The Life Sciences BC annual awards is our moment to acknowledge and honour the efforts of all those who have invested their life’s work in advancing successful health innovations. \nThe awards will recognize the achievements of individuals\, companies and organizations that have had success in endeavouring to advance discoveries from bench to bedside. At the center of the life sciences sector is improving the lives of patients. \nThe 23rd Annual Life Sciences BC Awards is presented by FARRIS.
URL:https://scienceinvancouver.com/event/23rd-annual-life-sciences-bc-awards/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/08/Copy-of-LSBC-Awards-Night-2021-Nominations.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210923T140000
DTEND;TZID=America/Vancouver:20210923T160000
DTSTAMP:20260404T132655
CREATED:20210813T195336Z
LAST-MODIFIED:20210813T195336Z
UID:26422-1632405600-1632412800@scienceinvancouver.com
SUMMARY:23rd Annual Life Sciences BC Awards
DESCRIPTION:The 23rd Annual Life Sciences BC Awards presented by FARRIS is an opportunity to celebrate the life science sector’s many achievements amongst peers\, family and friends. As Canada’s fastest-growing life sciences sector\, our British Columbia ecosystem has never been stronger seeing unprecedented momentum in scientific discovery\, innovation\, and attraction of capital and talent. In addition\, BC life science innovation has been at the forefront of the global response to COVID-19. The Life Sciences BC annual awards is our moment to acknowledge and honour the efforts of all those who have invested their life’s work in advancing successful health innovations. \nThe awards will recognize the achievements of individuals\, companies and organizations that have had success in endeavouring to advance discoveries from bench to bedside. At the center of the life sciences sector is improving the lives of patients. \nThe 23rd Annual Life Sciences BC Awards is presented by FARRIS.
URL:https://scienceinvancouver.com/event/23rd-annual-life-sciences-bc-awards-2/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/08/Copy-of-LSBC-Awards-Night-2021-Nominations.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210923T140000
DTEND;TZID=America/Vancouver:20210923T160000
DTSTAMP:20260404T132655
CREATED:20210813T195336Z
LAST-MODIFIED:20210813T195336Z
UID:28037-1632405600-1632412800@scienceinvancouver.com
SUMMARY:23rd Annual Life Sciences BC Awards
DESCRIPTION:The 23rd Annual Life Sciences BC Awards presented by FARRIS is an opportunity to celebrate the life science sector’s many achievements amongst peers\, family and friends. As Canada’s fastest-growing life sciences sector\, our British Columbia ecosystem has never been stronger seeing unprecedented momentum in scientific discovery\, innovation\, and attraction of capital and talent. In addition\, BC life science innovation has been at the forefront of the global response to COVID-19. The Life Sciences BC annual awards is our moment to acknowledge and honour the efforts of all those who have invested their life’s work in advancing successful health innovations. \nThe awards will recognize the achievements of individuals\, companies and organizations that have had success in endeavouring to advance discoveries from bench to bedside. At the center of the life sciences sector is improving the lives of patients. \nThe 23rd Annual Life Sciences BC Awards is presented by FARRIS.
URL:https://scienceinvancouver.com/event/23rd-annual-life-sciences-bc-awards-3/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/08/Copy-of-LSBC-Awards-Night-2021-Nominations.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210923T140000
DTEND;TZID=America/Vancouver:20210923T160000
DTSTAMP:20260404T132655
CREATED:20210813T195336Z
LAST-MODIFIED:20210813T195336Z
UID:31120-1632405600-1632412800@scienceinvancouver.com
SUMMARY:23rd Annual Life Sciences BC Awards
DESCRIPTION:The 23rd Annual Life Sciences BC Awards presented by FARRIS is an opportunity to celebrate the life science sector’s many achievements amongst peers\, family and friends. As Canada’s fastest-growing life sciences sector\, our British Columbia ecosystem has never been stronger seeing unprecedented momentum in scientific discovery\, innovation\, and attraction of capital and talent. In addition\, BC life science innovation has been at the forefront of the global response to COVID-19. The Life Sciences BC annual awards is our moment to acknowledge and honour the efforts of all those who have invested their life’s work in advancing successful health innovations. \nThe awards will recognize the achievements of individuals\, companies and organizations that have had success in endeavouring to advance discoveries from bench to bedside. At the center of the life sciences sector is improving the lives of patients. \nThe 23rd Annual Life Sciences BC Awards is presented by FARRIS.
URL:https://scienceinvancouver.com/event/23rd-annual-life-sciences-bc-awards-4/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/08/Copy-of-LSBC-Awards-Night-2021-Nominations.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210923T140000
DTEND;TZID=America/Vancouver:20210923T160000
DTSTAMP:20260404T132655
CREATED:20210813T195336Z
LAST-MODIFIED:20210813T195336Z
UID:32580-1632405600-1632412800@scienceinvancouver.com
SUMMARY:23rd Annual Life Sciences BC Awards
DESCRIPTION:The 23rd Annual Life Sciences BC Awards presented by FARRIS is an opportunity to celebrate the life science sector’s many achievements amongst peers\, family and friends. As Canada’s fastest-growing life sciences sector\, our British Columbia ecosystem has never been stronger seeing unprecedented momentum in scientific discovery\, innovation\, and attraction of capital and talent. In addition\, BC life science innovation has been at the forefront of the global response to COVID-19. The Life Sciences BC annual awards is our moment to acknowledge and honour the efforts of all those who have invested their life’s work in advancing successful health innovations. \nThe awards will recognize the achievements of individuals\, companies and organizations that have had success in endeavouring to advance discoveries from bench to bedside. At the center of the life sciences sector is improving the lives of patients. \nThe 23rd Annual Life Sciences BC Awards is presented by FARRIS.
URL:https://scienceinvancouver.com/event/23rd-annual-life-sciences-bc-awards-5/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/08/Copy-of-LSBC-Awards-Night-2021-Nominations.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210928T120000
DTEND;TZID=America/Vancouver:20210928T130000
DTSTAMP:20260404T132655
CREATED:20210922T154020Z
LAST-MODIFIED:20210927T175708Z
UID:18431-1632830400-1632834000@scienceinvancouver.com
SUMMARY:Science to Business Network (Vancouver-Victoria Chapter) Presents: Biotech Startups in BC
DESCRIPTION:Curious about entrepreneurship or biotechnology? If you’re not sure how your life sciences degree can translate into a career in medical biotechnology\, come learn about three Vancouver-based biotech startups that are making big waves in the science and health fields. Further\, learn how you can engage with UBC’s entrepreneurship department e@UBC to transform your own ideas into a business. \nThe Science to Business Network (www.s2bn.org) was founded 10 years ago to break down silos between universities\, industry\, government and the non-profit sector and to foster a culture of collaboration\, partnership and mutual understanding. Importantly\, the S2BN has been focused on building a network of innovative and creative individuals within and around STEM disciplines. Through panel discussions\, workshops\, mentoring programs\, a podcast and other collaborative initiatives\, the S2BN now has 9 chapters across Canada led by more than 70 grassroots volunteers whose activities now reach more than 2500 people a year. \nEvent objectives: \n-Learn about two local biotechnology companies and their distinct entrepreneurial journeys \n-Discover how entrepreneurship@UBC can help you prepare for a biotech startup career \n-Understand what it takes to launch a successful biotech startup in BC with recent examples \nVirtual online event details: \nDate: Tuesday\, September 28th\, 2021\nTime: 12-1pm PST\nRegister Free Online at: https://www.s2bn.org/upcoming-events \nCompanies Represented:\nEntrepreneurship @UBC (e@UBC) \nentrepreneurship@UBC propels UBC innovations out into the world through venture creation\, providing UBC students\, researchers\, faculty members\, alumni and staff with the resources\, networks\, and funding they need to succeed. As one of the world’s top 40 research universities with 80\,000 students\, faculty and staff and over $650M annual research funding\, UBC has long been a catalyst for innovation. Part of the Innovation UBC network\, entrepreneurship@UBC supports UBC ventures and entrepreneurs to generate social and economic impacts in B.C. and around the world. \nGenXys\nGenXys\, founded in 2014\, provides the world’s most comprehensive precision prescribing software to solve healthcare’s most pressing challenges. They currently offer four products involving precision prescribing software and pharmacogenetic solutions to prevent adverse drug reactions\, a leading cause of death in developed countries\, and personalize drug selection to increase drug efficacy. Powering every prescription with GenXys software improves medication safety\, increases drug efficacy and reduces healthcare costs. \nAdMare\nWith a wealth of scientific discovery\, Canada is primed to be a global leader in life sciences. By building companies\, ecosystems and talent\, adMare is helping build a thriving industry from sea to sea. Our 25+ portfolio companies have attracted more than $1.4B of investment\, have a combined value of over $3B\, and employ more than 900 Canadians. The adMare Academy has trained more than 260 alumni – 95% of whom are employed in the Canadian life sciences industry. \nChinook Therapeutics\nChinook is a clinical-stage biopharmaceutical company discovering\, developing and commercializing precision medicines for rare\, severe chronic kidney diseases with well-defined clinical pathways. Our lead clinical program\, atrasentan\, is an endothelin receptor antagonist that was in-licensed from AbbVie in 2019. The phase 3 ALIGN trial of atrasentan is currently enrolling patients with IgA nephropathy and the phase 2 AFFINITY trial of atrasentan is currently enrolling patients with proteinuric glomerular diseases. BION-1301\, an investigational anti-APRIL monoclonal antibody\, is being evaluated in a phase 1b trial for IgA nephropathy. We are also advancing CHK-336 for the treatment of primary hyperoxaluria towards a planned IND submission in late 2021/early 2022. In addition\, we are conducting research programs in other rare\, severe chronic kidney diseases. We seek to build our pipeline by leveraging insights in single cell RNA sequencing of patient kidney samples\, human-derived organoids and new translational models in order to discover and develop therapeutics with mechanisms of action targeted against key kidney disease pathways. \nSpeaker information:\nDr. Sean Lumb\, Associate Director\, Entrepreneurship UBC\nhttps://www.start.entrepreneurship.ubc.ca\nSean’s career spans 20 years of university IP commercialization and new venture creation. Sean completed his PhD in Chemistry at the University of British Columbia in 1998 and then joined UBC’s University-Industry Liaison Office\, working in increasingly senior roles to evaluate and commercialize chemistry-related licensing and startup opportunities ranging from advanced materials and coatings to drug development opportunities. \nSean left the UILO in 2006 to pursue an opportunity with Melbourne Ventures in Australia. At Melbourne Ventures Sean’s role was to license technology and spin out new ventures based on University of Melbourne intellectual property. Start-up successes include: Fibrotech Therapeutics (sold to Shire in May 2014)\, Procypra Therapeutics\, in Phase 2/3 clinical trials for neurodegenerative diseases\, and Clarity Pharmaceuticals\, which recently listed on the Australian Stock Exchange with the largest biotech listing in the history of the ASX. During his time at Melbourne Ventures\, Sean also participated on the investment committee of Uniseed\, a $100 million seed fund for university start-ups. \nAfter returning to Canada in 2012 Sean joined UBC to launch entrepreneurship@UBC (e@UBC) in 2013. Since the launch of e@UBC\, Sean has been involved in developing programming for\, recruiting\, and mentoring new venture teams from across the UBC research ecosystem. Sean’s current role as Associate Director\, Lab2Launch Venture Building Program at e@UBC involves supporting UBC’s researchers who are building startups around their research inventions. \nDr. Amie Phinney\, Senior Director of Partnerships\, AdMare\nAs the Sr. Director for the Program Development and Partnership team at adMare BioInnovations\, Amie Phinney uses her biomedical research and business administration background to create and guide scientific collaborations. Most recently\, Amie was at Northwestern University in Chicago\, where she established an academic-VC partnership aimed at translating academic discoveries into novel therapeutics. Prior to Northwestern University\, she gained extensive experience managing academic-pharma collaborations and biotech-pharma alliances while overseeing external partnerships with Abbott and AbbVie Labs in Chicago. Amie first transitioned into the pharmaceutical industry following post-docs at the University of Toronto and Free University of Amsterdam\, taking on Sr. Scientist and Project Director roles at Solvay Pharmaceuticals in the Netherlands. After five years leading pre-clinical research teams\, she joined the Program Management group to specialize in managing partnered scientific teams. Amie received her BSc at University of Guelph\, her PhD in Biomedical research at the University of Basel in Switzerland\, and her MBA at Lake Forest Graduate School of Management in Chicago. \nKarl Pringle\, Chief Executive Officer\, GenXys\nhttps://www.genxys.com\nKarl Pringle has a real passion for innovation driving digital transformation of outdated processes. The centuries old ‘trial and error’ approach to prescribing is one of these fossilized activities. Karl has guided GenXys through a transition from a UBC spinout pharmacogenetics company to a software business specializing in automated medication decision support software to enable accuracy and personalization in medication selection. Karl has extensive experience in turning early stage\, minimally viable software applications into market leaders and GenXys has become synonymous with innovation in precision prescribing with a vision of having every prescription globally\, powered by its software. \nAllison Gaw\, Executive Director\, Chinook Therapeutics\nhttps://www.chinooktx.com/\nAllison Gaw is the Executive Director\, Business and Corporate Development at Chinook Therapeutics\, a clinical stage drug development company working on precision medicines in kidney diseases here in Vancouver\, BC. Previously she held Business and Corporate Development\, IP Strategy\, and Financial Analysis roles at Sierra Oncology\, ProNAi Therapeutics\, Arbutus Biopharma and Tekmira. After her undergraduate\, Allison spent 5+ years in Healthcare consulting at LEK and BCG in San Francisco before moving into in-house biopharma positions here in Vancouver to leverage all the skills and experiences gained working with a number of West Coast Biopharmaceutical and MedTech companies to evaluate market entry\, growth strategy\, clinical development\, business development\, and operational excellence opportunities. Coming from a mixed background of research and consulting\, Allison enjoys working at the interface of science and business and helping others find that blended balance as well. She has a B.S. and M.S. in Biological Sciences from Stanford University and an MBA in Healthcare Management from the University of Pennsylvania Wharton School of Business. Outside of work\, Allison enjoys the active outdoor lifestyle made possible by living in such places like San Francisco and Vancouver – volleyball\, snowboarding\, hiking\, etc. \nWould you like to join our S2BN Vancouver-Victoria team?\nEmail us at: s2bnvancouver@s2bn.org
URL:https://scienceinvancouver.com/event/science-to-business-network-vancouver-victoria-chapter-presents-biotech-startups-in-bc/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/09/S2BN_biotechstartupsevent_poster_28Sept2021.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210928T120000
DTEND;TZID=America/Vancouver:20210928T130000
DTSTAMP:20260404T132655
CREATED:20210922T154020Z
LAST-MODIFIED:20210922T154020Z
UID:26440-1632830400-1632834000@scienceinvancouver.com
SUMMARY:Science to Business Network (Vancouver-Victoria Chapter) Presents: Biotech Startups in BC
DESCRIPTION:Curious about entrepreneurship or biotechnology? If you’re not sure how your life sciences degree can translate into a career in medical biotechnology\, come learn about three Vancouver-based biotech startups that are making big waves in the science and health fields. Further\, learn how you can engage with UBC’s entrepreneurship department e@UBC to transform your own ideas into a business. \nThe Science to Business Network (www.s2bn.org) was founded 10 years ago to break down silos between universities\, industry\, government and the non-profit sector and to foster a culture of collaboration\, partnership and mutual understanding. Importantly\, the S2BN has been focused on building a network of innovative and creative individuals within and around STEM disciplines. Through panel discussions\, workshops\, mentoring programs\, a podcast and other collaborative initiatives\, the S2BN now has 9 chapters across Canada led by more than 70 grassroots volunteers whose activities now reach more than 2500 people a year. \nEvent objectives: \n-Learn about two local biotechnology companies and their distinct entrepreneurial journeys \n-Discover how entrepreneurship@UBC can help you prepare for a biotech startup career \n-Understand what it takes to launch a successful biotech startup in BC with recent examples \nVirtual online event details: \nDate: Tuesday\, September 28th\, 2021\nTime: 12-1pm PST\nRegister Free Online at: https://www.s2bn.org/upcoming-events \nCompanies Represented:\nEntrepreneurship @UBC (e@UBC) \nentrepreneurship@UBC propels UBC innovations out into the world through venture creation\, providing UBC students\, researchers\, faculty members\, alumni and staff with the resources\, networks\, and funding they need to succeed. As one of the world’s top 40 research universities with 80\,000 students\, faculty and staff and over $650M annual research funding\, UBC has long been a catalyst for innovation. Part of the Innovation UBC network\, entrepreneurship@UBC supports UBC ventures and entrepreneurs to generate social and economic impacts in B.C. and around the world. \nGenXys\nGenXys\, founded in 2014\, provides the world’s most comprehensive precision prescribing software to solve healthcare’s most pressing challenges. They currently offer four products involving precision prescribing software and pharmacogenetic solutions to prevent adverse drug reactions\, a leading cause of death in developed countries\, and personalize drug selection to increase drug efficacy. Powering every prescription with GenXys software improves medication safety\, increases drug efficacy and reduces healthcare costs. \nAdMare\nWith a wealth of scientific discovery\, Canada is primed to be a global leader in life sciences. By building companies\, ecosystems and talent\, adMare is helping build a thriving industry from sea to sea. Our 25+ portfolio companies have attracted more than $1.4B of investment\, have a combined value of over $3B\, and employ more than 900 Canadians. The adMare Academy has trained more than 260 alumni – 95% of whom are employed in the Canadian life sciences industry. \nChinook Therapeutics\nChinook is a clinical-stage biopharmaceutical company discovering\, developing and commercializing precision medicines for rare\, severe chronic kidney diseases with well-defined clinical pathways. Our lead clinical program\, atrasentan\, is an endothelin receptor antagonist that was in-licensed from AbbVie in 2019. The phase 3 ALIGN trial of atrasentan is currently enrolling patients with IgA nephropathy and the phase 2 AFFINITY trial of atrasentan is currently enrolling patients with proteinuric glomerular diseases. BION-1301\, an investigational anti-APRIL monoclonal antibody\, is being evaluated in a phase 1b trial for IgA nephropathy. We are also advancing CHK-336 for the treatment of primary hyperoxaluria towards a planned IND submission in late 2021/early 2022. In addition\, we are conducting research programs in other rare\, severe chronic kidney diseases. We seek to build our pipeline by leveraging insights in single cell RNA sequencing of patient kidney samples\, human-derived organoids and new translational models in order to discover and develop therapeutics with mechanisms of action targeted against key kidney disease pathways. \nSpeaker information:\nDr. Sean Lumb\, Associate Director\, Entrepreneurship UBC\nhttps://www.start.entrepreneurship.ubc.ca\nSean’s career spans 20 years of university IP commercialization and new venture creation. Sean completed his PhD in Chemistry at the University of British Columbia in 1998 and then joined UBC’s University-Industry Liaison Office\, working in increasingly senior roles to evaluate and commercialize chemistry-related licensing and startup opportunities ranging from advanced materials and coatings to drug development opportunities. \nSean left the UILO in 2006 to pursue an opportunity with Melbourne Ventures in Australia. At Melbourne Ventures Sean’s role was to license technology and spin out new ventures based on University of Melbourne intellectual property. Start-up successes include: Fibrotech Therapeutics (sold to Shire in May 2014)\, Procypra Therapeutics\, in Phase 2/3 clinical trials for neurodegenerative diseases\, and Clarity Pharmaceuticals\, which recently listed on the Australian Stock Exchange with the largest biotech listing in the history of the ASX. During his time at Melbourne Ventures\, Sean also participated on the investment committee of Uniseed\, a $100 million seed fund for university start-ups. \nAfter returning to Canada in 2012 Sean joined UBC to launch entrepreneurship@UBC (e@UBC) in 2013. Since the launch of e@UBC\, Sean has been involved in developing programming for\, recruiting\, and mentoring new venture teams from across the UBC research ecosystem. Sean’s current role as Associate Director\, Lab2Launch Venture Building Program at e@UBC involves supporting UBC’s researchers who are building startups around their research inventions. \nDr. Amie Phinney\, Senior Director of Partnerships\, AdMare\nAs the Sr. Director for the Program Development and Partnership team at adMare BioInnovations\, Amie Phinney uses her biomedical research and business administration background to create and guide scientific collaborations. Most recently\, Amie was at Northwestern University in Chicago\, where she established an academic-VC partnership aimed at translating academic discoveries into novel therapeutics. Prior to Northwestern University\, she gained extensive experience managing academic-pharma collaborations and biotech-pharma alliances while overseeing external partnerships with Abbott and AbbVie Labs in Chicago. Amie first transitioned into the pharmaceutical industry following post-docs at the University of Toronto and Free University of Amsterdam\, taking on Sr. Scientist and Project Director roles at Solvay Pharmaceuticals in the Netherlands. After five years leading pre-clinical research teams\, she joined the Program Management group to specialize in managing partnered scientific teams. Amie received her BSc at University of Guelph\, her PhD in Biomedical research at the University of Basel in Switzerland\, and her MBA at Lake Forest Graduate School of Management in Chicago. \nKarl Pringle\, Chief Executive Officer\, GenXys\nhttps://www.genxys.com\nKarl Pringle has a real passion for innovation driving digital transformation of outdated processes. The centuries old ‘trial and error’ approach to prescribing is one of these fossilized activities. Karl has guided GenXys through a transition from a UBC spinout pharmacogenetics company to a software business specializing in automated medication decision support software to enable accuracy and personalization in medication selection. Karl has extensive experience in turning early stage\, minimally viable software applications into market leaders and GenXys has become synonymous with innovation in precision prescribing with a vision of having every prescription globally\, powered by its software. \nAllison Gaw\, Executive Director\, Chinook Therapeutics\nhttps://www.chinooktx.com/\nAllison Gaw is the Executive Director\, Business and Corporate Development at Chinook Therapeutics\, a clinical stage drug development company working on precision medicines in kidney diseases here in Vancouver\, BC. Previously she held Business and Corporate Development\, IP Strategy\, and Financial Analysis roles at Sierra Oncology\, ProNAi Therapeutics\, Arbutus Biopharma and Tekmira. After her undergraduate\, Allison spent 5+ years in Healthcare consulting at LEK and BCG in San Francisco before moving into in-house biopharma positions here in Vancouver to leverage all the skills and experiences gained working with a number of West Coast Biopharmaceutical and MedTech companies to evaluate market entry\, growth strategy\, clinical development\, business development\, and operational excellence opportunities. Coming from a mixed background of research and consulting\, Allison enjoys working at the interface of science and business and helping others find that blended balance as well. She has a B.S. and M.S. in Biological Sciences from Stanford University and an MBA in Healthcare Management from the University of Pennsylvania Wharton School of Business. Outside of work\, Allison enjoys the active outdoor lifestyle made possible by living in such places like San Francisco and Vancouver – volleyball\, snowboarding\, hiking\, etc. \nWould you like to join our S2BN Vancouver-Victoria team?\nEmail us at: s2bnvancouver@s2bn.org
URL:https://scienceinvancouver.com/event/science-to-business-network-vancouver-victoria-chapter-presents-biotech-startups-in-bc-2/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/09/S2BN_biotechstartupsevent_poster_28Sept2021.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210928T120000
DTEND;TZID=America/Vancouver:20210928T130000
DTSTAMP:20260404T132655
CREATED:20210922T154020Z
LAST-MODIFIED:20210922T154020Z
UID:28056-1632830400-1632834000@scienceinvancouver.com
SUMMARY:Science to Business Network (Vancouver-Victoria Chapter) Presents: Biotech Startups in BC
DESCRIPTION:Curious about entrepreneurship or biotechnology? If you’re not sure how your life sciences degree can translate into a career in medical biotechnology\, come learn about three Vancouver-based biotech startups that are making big waves in the science and health fields. Further\, learn how you can engage with UBC’s entrepreneurship department e@UBC to transform your own ideas into a business. \nThe Science to Business Network (www.s2bn.org) was founded 10 years ago to break down silos between universities\, industry\, government and the non-profit sector and to foster a culture of collaboration\, partnership and mutual understanding. Importantly\, the S2BN has been focused on building a network of innovative and creative individuals within and around STEM disciplines. Through panel discussions\, workshops\, mentoring programs\, a podcast and other collaborative initiatives\, the S2BN now has 9 chapters across Canada led by more than 70 grassroots volunteers whose activities now reach more than 2500 people a year. \nEvent objectives: \n-Learn about two local biotechnology companies and their distinct entrepreneurial journeys \n-Discover how entrepreneurship@UBC can help you prepare for a biotech startup career \n-Understand what it takes to launch a successful biotech startup in BC with recent examples \nVirtual online event details: \nDate: Tuesday\, September 28th\, 2021\nTime: 12-1pm PST\nRegister Free Online at: https://www.s2bn.org/upcoming-events \nCompanies Represented:\nEntrepreneurship @UBC (e@UBC) \nentrepreneurship@UBC propels UBC innovations out into the world through venture creation\, providing UBC students\, researchers\, faculty members\, alumni and staff with the resources\, networks\, and funding they need to succeed. As one of the world’s top 40 research universities with 80\,000 students\, faculty and staff and over $650M annual research funding\, UBC has long been a catalyst for innovation. Part of the Innovation UBC network\, entrepreneurship@UBC supports UBC ventures and entrepreneurs to generate social and economic impacts in B.C. and around the world. \nGenXys\nGenXys\, founded in 2014\, provides the world’s most comprehensive precision prescribing software to solve healthcare’s most pressing challenges. They currently offer four products involving precision prescribing software and pharmacogenetic solutions to prevent adverse drug reactions\, a leading cause of death in developed countries\, and personalize drug selection to increase drug efficacy. Powering every prescription with GenXys software improves medication safety\, increases drug efficacy and reduces healthcare costs. \nAdMare\nWith a wealth of scientific discovery\, Canada is primed to be a global leader in life sciences. By building companies\, ecosystems and talent\, adMare is helping build a thriving industry from sea to sea. Our 25+ portfolio companies have attracted more than $1.4B of investment\, have a combined value of over $3B\, and employ more than 900 Canadians. The adMare Academy has trained more than 260 alumni – 95% of whom are employed in the Canadian life sciences industry. \nChinook Therapeutics\nChinook is a clinical-stage biopharmaceutical company discovering\, developing and commercializing precision medicines for rare\, severe chronic kidney diseases with well-defined clinical pathways. Our lead clinical program\, atrasentan\, is an endothelin receptor antagonist that was in-licensed from AbbVie in 2019. The phase 3 ALIGN trial of atrasentan is currently enrolling patients with IgA nephropathy and the phase 2 AFFINITY trial of atrasentan is currently enrolling patients with proteinuric glomerular diseases. BION-1301\, an investigational anti-APRIL monoclonal antibody\, is being evaluated in a phase 1b trial for IgA nephropathy. We are also advancing CHK-336 for the treatment of primary hyperoxaluria towards a planned IND submission in late 2021/early 2022. In addition\, we are conducting research programs in other rare\, severe chronic kidney diseases. We seek to build our pipeline by leveraging insights in single cell RNA sequencing of patient kidney samples\, human-derived organoids and new translational models in order to discover and develop therapeutics with mechanisms of action targeted against key kidney disease pathways. \nSpeaker information:\nDr. Sean Lumb\, Associate Director\, Entrepreneurship UBC\nhttps://www.start.entrepreneurship.ubc.ca\nSean’s career spans 20 years of university IP commercialization and new venture creation. Sean completed his PhD in Chemistry at the University of British Columbia in 1998 and then joined UBC’s University-Industry Liaison Office\, working in increasingly senior roles to evaluate and commercialize chemistry-related licensing and startup opportunities ranging from advanced materials and coatings to drug development opportunities. \nSean left the UILO in 2006 to pursue an opportunity with Melbourne Ventures in Australia. At Melbourne Ventures Sean’s role was to license technology and spin out new ventures based on University of Melbourne intellectual property. Start-up successes include: Fibrotech Therapeutics (sold to Shire in May 2014)\, Procypra Therapeutics\, in Phase 2/3 clinical trials for neurodegenerative diseases\, and Clarity Pharmaceuticals\, which recently listed on the Australian Stock Exchange with the largest biotech listing in the history of the ASX. During his time at Melbourne Ventures\, Sean also participated on the investment committee of Uniseed\, a $100 million seed fund for university start-ups. \nAfter returning to Canada in 2012 Sean joined UBC to launch entrepreneurship@UBC (e@UBC) in 2013. Since the launch of e@UBC\, Sean has been involved in developing programming for\, recruiting\, and mentoring new venture teams from across the UBC research ecosystem. Sean’s current role as Associate Director\, Lab2Launch Venture Building Program at e@UBC involves supporting UBC’s researchers who are building startups around their research inventions. \nDr. Amie Phinney\, Senior Director of Partnerships\, AdMare\nAs the Sr. Director for the Program Development and Partnership team at adMare BioInnovations\, Amie Phinney uses her biomedical research and business administration background to create and guide scientific collaborations. Most recently\, Amie was at Northwestern University in Chicago\, where she established an academic-VC partnership aimed at translating academic discoveries into novel therapeutics. Prior to Northwestern University\, she gained extensive experience managing academic-pharma collaborations and biotech-pharma alliances while overseeing external partnerships with Abbott and AbbVie Labs in Chicago. Amie first transitioned into the pharmaceutical industry following post-docs at the University of Toronto and Free University of Amsterdam\, taking on Sr. Scientist and Project Director roles at Solvay Pharmaceuticals in the Netherlands. After five years leading pre-clinical research teams\, she joined the Program Management group to specialize in managing partnered scientific teams. Amie received her BSc at University of Guelph\, her PhD in Biomedical research at the University of Basel in Switzerland\, and her MBA at Lake Forest Graduate School of Management in Chicago. \nKarl Pringle\, Chief Executive Officer\, GenXys\nhttps://www.genxys.com\nKarl Pringle has a real passion for innovation driving digital transformation of outdated processes. The centuries old ‘trial and error’ approach to prescribing is one of these fossilized activities. Karl has guided GenXys through a transition from a UBC spinout pharmacogenetics company to a software business specializing in automated medication decision support software to enable accuracy and personalization in medication selection. Karl has extensive experience in turning early stage\, minimally viable software applications into market leaders and GenXys has become synonymous with innovation in precision prescribing with a vision of having every prescription globally\, powered by its software. \nAllison Gaw\, Executive Director\, Chinook Therapeutics\nhttps://www.chinooktx.com/\nAllison Gaw is the Executive Director\, Business and Corporate Development at Chinook Therapeutics\, a clinical stage drug development company working on precision medicines in kidney diseases here in Vancouver\, BC. Previously she held Business and Corporate Development\, IP Strategy\, and Financial Analysis roles at Sierra Oncology\, ProNAi Therapeutics\, Arbutus Biopharma and Tekmira. After her undergraduate\, Allison spent 5+ years in Healthcare consulting at LEK and BCG in San Francisco before moving into in-house biopharma positions here in Vancouver to leverage all the skills and experiences gained working with a number of West Coast Biopharmaceutical and MedTech companies to evaluate market entry\, growth strategy\, clinical development\, business development\, and operational excellence opportunities. Coming from a mixed background of research and consulting\, Allison enjoys working at the interface of science and business and helping others find that blended balance as well. She has a B.S. and M.S. in Biological Sciences from Stanford University and an MBA in Healthcare Management from the University of Pennsylvania Wharton School of Business. Outside of work\, Allison enjoys the active outdoor lifestyle made possible by living in such places like San Francisco and Vancouver – volleyball\, snowboarding\, hiking\, etc. \nWould you like to join our S2BN Vancouver-Victoria team?\nEmail us at: s2bnvancouver@s2bn.org
URL:https://scienceinvancouver.com/event/science-to-business-network-vancouver-victoria-chapter-presents-biotech-startups-in-bc-3/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/09/S2BN_biotechstartupsevent_poster_28Sept2021.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210928T120000
DTEND;TZID=America/Vancouver:20210928T130000
DTSTAMP:20260404T132655
CREATED:20210922T154020Z
LAST-MODIFIED:20210922T154020Z
UID:31138-1632830400-1632834000@scienceinvancouver.com
SUMMARY:Science to Business Network (Vancouver-Victoria Chapter) Presents: Biotech Startups in BC
DESCRIPTION:Curious about entrepreneurship or biotechnology? If you’re not sure how your life sciences degree can translate into a career in medical biotechnology\, come learn about three Vancouver-based biotech startups that are making big waves in the science and health fields. Further\, learn how you can engage with UBC’s entrepreneurship department e@UBC to transform your own ideas into a business. \nThe Science to Business Network (www.s2bn.org) was founded 10 years ago to break down silos between universities\, industry\, government and the non-profit sector and to foster a culture of collaboration\, partnership and mutual understanding. Importantly\, the S2BN has been focused on building a network of innovative and creative individuals within and around STEM disciplines. Through panel discussions\, workshops\, mentoring programs\, a podcast and other collaborative initiatives\, the S2BN now has 9 chapters across Canada led by more than 70 grassroots volunteers whose activities now reach more than 2500 people a year. \nEvent objectives: \n-Learn about two local biotechnology companies and their distinct entrepreneurial journeys \n-Discover how entrepreneurship@UBC can help you prepare for a biotech startup career \n-Understand what it takes to launch a successful biotech startup in BC with recent examples \nVirtual online event details: \nDate: Tuesday\, September 28th\, 2021\nTime: 12-1pm PST\nRegister Free Online at: https://www.s2bn.org/upcoming-events \nCompanies Represented:\nEntrepreneurship @UBC (e@UBC) \nentrepreneurship@UBC propels UBC innovations out into the world through venture creation\, providing UBC students\, researchers\, faculty members\, alumni and staff with the resources\, networks\, and funding they need to succeed. As one of the world’s top 40 research universities with 80\,000 students\, faculty and staff and over $650M annual research funding\, UBC has long been a catalyst for innovation. Part of the Innovation UBC network\, entrepreneurship@UBC supports UBC ventures and entrepreneurs to generate social and economic impacts in B.C. and around the world. \nGenXys\nGenXys\, founded in 2014\, provides the world’s most comprehensive precision prescribing software to solve healthcare’s most pressing challenges. They currently offer four products involving precision prescribing software and pharmacogenetic solutions to prevent adverse drug reactions\, a leading cause of death in developed countries\, and personalize drug selection to increase drug efficacy. Powering every prescription with GenXys software improves medication safety\, increases drug efficacy and reduces healthcare costs. \nAdMare\nWith a wealth of scientific discovery\, Canada is primed to be a global leader in life sciences. By building companies\, ecosystems and talent\, adMare is helping build a thriving industry from sea to sea. Our 25+ portfolio companies have attracted more than $1.4B of investment\, have a combined value of over $3B\, and employ more than 900 Canadians. The adMare Academy has trained more than 260 alumni – 95% of whom are employed in the Canadian life sciences industry. \nChinook Therapeutics\nChinook is a clinical-stage biopharmaceutical company discovering\, developing and commercializing precision medicines for rare\, severe chronic kidney diseases with well-defined clinical pathways. Our lead clinical program\, atrasentan\, is an endothelin receptor antagonist that was in-licensed from AbbVie in 2019. The phase 3 ALIGN trial of atrasentan is currently enrolling patients with IgA nephropathy and the phase 2 AFFINITY trial of atrasentan is currently enrolling patients with proteinuric glomerular diseases. BION-1301\, an investigational anti-APRIL monoclonal antibody\, is being evaluated in a phase 1b trial for IgA nephropathy. We are also advancing CHK-336 for the treatment of primary hyperoxaluria towards a planned IND submission in late 2021/early 2022. In addition\, we are conducting research programs in other rare\, severe chronic kidney diseases. We seek to build our pipeline by leveraging insights in single cell RNA sequencing of patient kidney samples\, human-derived organoids and new translational models in order to discover and develop therapeutics with mechanisms of action targeted against key kidney disease pathways. \nSpeaker information:\nDr. Sean Lumb\, Associate Director\, Entrepreneurship UBC\nhttps://www.start.entrepreneurship.ubc.ca\nSean’s career spans 20 years of university IP commercialization and new venture creation. Sean completed his PhD in Chemistry at the University of British Columbia in 1998 and then joined UBC’s University-Industry Liaison Office\, working in increasingly senior roles to evaluate and commercialize chemistry-related licensing and startup opportunities ranging from advanced materials and coatings to drug development opportunities. \nSean left the UILO in 2006 to pursue an opportunity with Melbourne Ventures in Australia. At Melbourne Ventures Sean’s role was to license technology and spin out new ventures based on University of Melbourne intellectual property. Start-up successes include: Fibrotech Therapeutics (sold to Shire in May 2014)\, Procypra Therapeutics\, in Phase 2/3 clinical trials for neurodegenerative diseases\, and Clarity Pharmaceuticals\, which recently listed on the Australian Stock Exchange with the largest biotech listing in the history of the ASX. During his time at Melbourne Ventures\, Sean also participated on the investment committee of Uniseed\, a $100 million seed fund for university start-ups. \nAfter returning to Canada in 2012 Sean joined UBC to launch entrepreneurship@UBC (e@UBC) in 2013. Since the launch of e@UBC\, Sean has been involved in developing programming for\, recruiting\, and mentoring new venture teams from across the UBC research ecosystem. Sean’s current role as Associate Director\, Lab2Launch Venture Building Program at e@UBC involves supporting UBC’s researchers who are building startups around their research inventions. \nDr. Amie Phinney\, Senior Director of Partnerships\, AdMare\nAs the Sr. Director for the Program Development and Partnership team at adMare BioInnovations\, Amie Phinney uses her biomedical research and business administration background to create and guide scientific collaborations. Most recently\, Amie was at Northwestern University in Chicago\, where she established an academic-VC partnership aimed at translating academic discoveries into novel therapeutics. Prior to Northwestern University\, she gained extensive experience managing academic-pharma collaborations and biotech-pharma alliances while overseeing external partnerships with Abbott and AbbVie Labs in Chicago. Amie first transitioned into the pharmaceutical industry following post-docs at the University of Toronto and Free University of Amsterdam\, taking on Sr. Scientist and Project Director roles at Solvay Pharmaceuticals in the Netherlands. After five years leading pre-clinical research teams\, she joined the Program Management group to specialize in managing partnered scientific teams. Amie received her BSc at University of Guelph\, her PhD in Biomedical research at the University of Basel in Switzerland\, and her MBA at Lake Forest Graduate School of Management in Chicago. \nKarl Pringle\, Chief Executive Officer\, GenXys\nhttps://www.genxys.com\nKarl Pringle has a real passion for innovation driving digital transformation of outdated processes. The centuries old ‘trial and error’ approach to prescribing is one of these fossilized activities. Karl has guided GenXys through a transition from a UBC spinout pharmacogenetics company to a software business specializing in automated medication decision support software to enable accuracy and personalization in medication selection. Karl has extensive experience in turning early stage\, minimally viable software applications into market leaders and GenXys has become synonymous with innovation in precision prescribing with a vision of having every prescription globally\, powered by its software. \nAllison Gaw\, Executive Director\, Chinook Therapeutics\nhttps://www.chinooktx.com/\nAllison Gaw is the Executive Director\, Business and Corporate Development at Chinook Therapeutics\, a clinical stage drug development company working on precision medicines in kidney diseases here in Vancouver\, BC. Previously she held Business and Corporate Development\, IP Strategy\, and Financial Analysis roles at Sierra Oncology\, ProNAi Therapeutics\, Arbutus Biopharma and Tekmira. After her undergraduate\, Allison spent 5+ years in Healthcare consulting at LEK and BCG in San Francisco before moving into in-house biopharma positions here in Vancouver to leverage all the skills and experiences gained working with a number of West Coast Biopharmaceutical and MedTech companies to evaluate market entry\, growth strategy\, clinical development\, business development\, and operational excellence opportunities. Coming from a mixed background of research and consulting\, Allison enjoys working at the interface of science and business and helping others find that blended balance as well. She has a B.S. and M.S. in Biological Sciences from Stanford University and an MBA in Healthcare Management from the University of Pennsylvania Wharton School of Business. Outside of work\, Allison enjoys the active outdoor lifestyle made possible by living in such places like San Francisco and Vancouver – volleyball\, snowboarding\, hiking\, etc. \nWould you like to join our S2BN Vancouver-Victoria team?\nEmail us at: s2bnvancouver@s2bn.org
URL:https://scienceinvancouver.com/event/science-to-business-network-vancouver-victoria-chapter-presents-biotech-startups-in-bc-4/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/09/S2BN_biotechstartupsevent_poster_28Sept2021.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210928T120000
DTEND;TZID=America/Vancouver:20210928T130000
DTSTAMP:20260404T132655
CREATED:20210922T154020Z
LAST-MODIFIED:20210922T154020Z
UID:32598-1632830400-1632834000@scienceinvancouver.com
SUMMARY:Science to Business Network (Vancouver-Victoria Chapter) Presents: Biotech Startups in BC
DESCRIPTION:Curious about entrepreneurship or biotechnology? If you’re not sure how your life sciences degree can translate into a career in medical biotechnology\, come learn about three Vancouver-based biotech startups that are making big waves in the science and health fields. Further\, learn how you can engage with UBC’s entrepreneurship department e@UBC to transform your own ideas into a business. \nThe Science to Business Network (www.s2bn.org) was founded 10 years ago to break down silos between universities\, industry\, government and the non-profit sector and to foster a culture of collaboration\, partnership and mutual understanding. Importantly\, the S2BN has been focused on building a network of innovative and creative individuals within and around STEM disciplines. Through panel discussions\, workshops\, mentoring programs\, a podcast and other collaborative initiatives\, the S2BN now has 9 chapters across Canada led by more than 70 grassroots volunteers whose activities now reach more than 2500 people a year. \nEvent objectives: \n-Learn about two local biotechnology companies and their distinct entrepreneurial journeys \n-Discover how entrepreneurship@UBC can help you prepare for a biotech startup career \n-Understand what it takes to launch a successful biotech startup in BC with recent examples \nVirtual online event details: \nDate: Tuesday\, September 28th\, 2021\nTime: 12-1pm PST\nRegister Free Online at: https://www.s2bn.org/upcoming-events \nCompanies Represented:\nEntrepreneurship @UBC (e@UBC) \nentrepreneurship@UBC propels UBC innovations out into the world through venture creation\, providing UBC students\, researchers\, faculty members\, alumni and staff with the resources\, networks\, and funding they need to succeed. As one of the world’s top 40 research universities with 80\,000 students\, faculty and staff and over $650M annual research funding\, UBC has long been a catalyst for innovation. Part of the Innovation UBC network\, entrepreneurship@UBC supports UBC ventures and entrepreneurs to generate social and economic impacts in B.C. and around the world. \nGenXys\nGenXys\, founded in 2014\, provides the world’s most comprehensive precision prescribing software to solve healthcare’s most pressing challenges. They currently offer four products involving precision prescribing software and pharmacogenetic solutions to prevent adverse drug reactions\, a leading cause of death in developed countries\, and personalize drug selection to increase drug efficacy. Powering every prescription with GenXys software improves medication safety\, increases drug efficacy and reduces healthcare costs. \nAdMare\nWith a wealth of scientific discovery\, Canada is primed to be a global leader in life sciences. By building companies\, ecosystems and talent\, adMare is helping build a thriving industry from sea to sea. Our 25+ portfolio companies have attracted more than $1.4B of investment\, have a combined value of over $3B\, and employ more than 900 Canadians. The adMare Academy has trained more than 260 alumni – 95% of whom are employed in the Canadian life sciences industry. \nChinook Therapeutics\nChinook is a clinical-stage biopharmaceutical company discovering\, developing and commercializing precision medicines for rare\, severe chronic kidney diseases with well-defined clinical pathways. Our lead clinical program\, atrasentan\, is an endothelin receptor antagonist that was in-licensed from AbbVie in 2019. The phase 3 ALIGN trial of atrasentan is currently enrolling patients with IgA nephropathy and the phase 2 AFFINITY trial of atrasentan is currently enrolling patients with proteinuric glomerular diseases. BION-1301\, an investigational anti-APRIL monoclonal antibody\, is being evaluated in a phase 1b trial for IgA nephropathy. We are also advancing CHK-336 for the treatment of primary hyperoxaluria towards a planned IND submission in late 2021/early 2022. In addition\, we are conducting research programs in other rare\, severe chronic kidney diseases. We seek to build our pipeline by leveraging insights in single cell RNA sequencing of patient kidney samples\, human-derived organoids and new translational models in order to discover and develop therapeutics with mechanisms of action targeted against key kidney disease pathways. \nSpeaker information:\nDr. Sean Lumb\, Associate Director\, Entrepreneurship UBC\nhttps://www.start.entrepreneurship.ubc.ca\nSean’s career spans 20 years of university IP commercialization and new venture creation. Sean completed his PhD in Chemistry at the University of British Columbia in 1998 and then joined UBC’s University-Industry Liaison Office\, working in increasingly senior roles to evaluate and commercialize chemistry-related licensing and startup opportunities ranging from advanced materials and coatings to drug development opportunities. \nSean left the UILO in 2006 to pursue an opportunity with Melbourne Ventures in Australia. At Melbourne Ventures Sean’s role was to license technology and spin out new ventures based on University of Melbourne intellectual property. Start-up successes include: Fibrotech Therapeutics (sold to Shire in May 2014)\, Procypra Therapeutics\, in Phase 2/3 clinical trials for neurodegenerative diseases\, and Clarity Pharmaceuticals\, which recently listed on the Australian Stock Exchange with the largest biotech listing in the history of the ASX. During his time at Melbourne Ventures\, Sean also participated on the investment committee of Uniseed\, a $100 million seed fund for university start-ups. \nAfter returning to Canada in 2012 Sean joined UBC to launch entrepreneurship@UBC (e@UBC) in 2013. Since the launch of e@UBC\, Sean has been involved in developing programming for\, recruiting\, and mentoring new venture teams from across the UBC research ecosystem. Sean’s current role as Associate Director\, Lab2Launch Venture Building Program at e@UBC involves supporting UBC’s researchers who are building startups around their research inventions. \nDr. Amie Phinney\, Senior Director of Partnerships\, AdMare\nAs the Sr. Director for the Program Development and Partnership team at adMare BioInnovations\, Amie Phinney uses her biomedical research and business administration background to create and guide scientific collaborations. Most recently\, Amie was at Northwestern University in Chicago\, where she established an academic-VC partnership aimed at translating academic discoveries into novel therapeutics. Prior to Northwestern University\, she gained extensive experience managing academic-pharma collaborations and biotech-pharma alliances while overseeing external partnerships with Abbott and AbbVie Labs in Chicago. Amie first transitioned into the pharmaceutical industry following post-docs at the University of Toronto and Free University of Amsterdam\, taking on Sr. Scientist and Project Director roles at Solvay Pharmaceuticals in the Netherlands. After five years leading pre-clinical research teams\, she joined the Program Management group to specialize in managing partnered scientific teams. Amie received her BSc at University of Guelph\, her PhD in Biomedical research at the University of Basel in Switzerland\, and her MBA at Lake Forest Graduate School of Management in Chicago. \nKarl Pringle\, Chief Executive Officer\, GenXys\nhttps://www.genxys.com\nKarl Pringle has a real passion for innovation driving digital transformation of outdated processes. The centuries old ‘trial and error’ approach to prescribing is one of these fossilized activities. Karl has guided GenXys through a transition from a UBC spinout pharmacogenetics company to a software business specializing in automated medication decision support software to enable accuracy and personalization in medication selection. Karl has extensive experience in turning early stage\, minimally viable software applications into market leaders and GenXys has become synonymous with innovation in precision prescribing with a vision of having every prescription globally\, powered by its software. \nAllison Gaw\, Executive Director\, Chinook Therapeutics\nhttps://www.chinooktx.com/\nAllison Gaw is the Executive Director\, Business and Corporate Development at Chinook Therapeutics\, a clinical stage drug development company working on precision medicines in kidney diseases here in Vancouver\, BC. Previously she held Business and Corporate Development\, IP Strategy\, and Financial Analysis roles at Sierra Oncology\, ProNAi Therapeutics\, Arbutus Biopharma and Tekmira. After her undergraduate\, Allison spent 5+ years in Healthcare consulting at LEK and BCG in San Francisco before moving into in-house biopharma positions here in Vancouver to leverage all the skills and experiences gained working with a number of West Coast Biopharmaceutical and MedTech companies to evaluate market entry\, growth strategy\, clinical development\, business development\, and operational excellence opportunities. Coming from a mixed background of research and consulting\, Allison enjoys working at the interface of science and business and helping others find that blended balance as well. She has a B.S. and M.S. in Biological Sciences from Stanford University and an MBA in Healthcare Management from the University of Pennsylvania Wharton School of Business. Outside of work\, Allison enjoys the active outdoor lifestyle made possible by living in such places like San Francisco and Vancouver – volleyball\, snowboarding\, hiking\, etc. \nWould you like to join our S2BN Vancouver-Victoria team?\nEmail us at: s2bnvancouver@s2bn.org
URL:https://scienceinvancouver.com/event/science-to-business-network-vancouver-victoria-chapter-presents-biotech-startups-in-bc-5/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/09/S2BN_biotechstartupsevent_poster_28Sept2021.jpg
END:VEVENT
END:VCALENDAR